Hudson Acquisition I in a proxy filing wants shareholders to approve a nine-month extension on the SPAC’s completion deadline — up to April 18, 2024. If approved, the sponsor would deposit $80,000 into trust for each month required.
Hudson I announced in April that it had signed a non-binding letter of intent with a target company for a potential business combination, although there has been no news since regarding that development, nor is the LOI mentioned in the SPAC’s latest regulatory filing.
The target is said to be a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, according to a press release.
The SPAC raised $60 million in October with plans to target US technology companies, while specifically avoiding any companies in China, Hong Kong or Macau. Read more.
